Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
body composition
head and neck (H&N) cancer
immune checkpoint inhibitors
immune-related adverse events (irAE)
muscle mass
sarcopenia
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
04
2021
accepted:
08
06
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoints inhibitors (ICI). A single-institutional, retrospective study was performed including 61 consecutive patients of R/M HNSCC diagnosed between July 2015 and December 2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier estimations were used to detect overall survival (OS) and progression-free survival (PFS). Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3. Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate (HR, 2.06; 95% CI, 1.14-3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95% CI, 1.29-6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84; 95% CI, 1.08-3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20-1.54; p = 0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three had low SMI. Low SMI before ICI treatment in R/M HNSCC patients had a negative impact on OS and PFS. Further prospective research is needed to confirm the role of body composition as a predictive biomarker in ICI treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoints inhibitors (ICI).
METHODS
METHODS
A single-institutional, retrospective study was performed including 61 consecutive patients of R/M HNSCC diagnosed between July 2015 and December 2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier estimations were used to detect overall survival (OS) and progression-free survival (PFS). Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3.
RESULTS
RESULTS
Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate (HR, 2.06; 95% CI, 1.14-3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95% CI, 1.29-6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84; 95% CI, 1.08-3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20-1.54; p = 0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three had low SMI.
CONCLUSIONS
CONCLUSIONS
Low SMI before ICI treatment in R/M HNSCC patients had a negative impact on OS and PFS. Further prospective research is needed to confirm the role of body composition as a predictive biomarker in ICI treatment.
Identifiants
pubmed: 34249760
doi: 10.3389/fonc.2021.699668
pmc: PMC8267860
doi:
Types de publication
Journal Article
Langues
eng
Pagination
699668Informations de copyright
Copyright © 2021 Arribas, Plana, Taberna, Sospedra, Vilariño, Oliva, Pallarés, González Tampán, Del Rio, Mesia and Baracos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
Cytokine Growth Factor Rev. 2017 Feb;33:73-82
pubmed: 27765498
Radiother Oncol. 2020 Jun;147:103-110
pubmed: 32251949
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
JAMA Oncol. 2016 Jun 1;2(6):782-9
pubmed: 26891703
Physiol Rev. 2008 Oct;88(4):1379-406
pubmed: 18923185
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Sci Rep. 2020 Jan 29;10(1):1456
pubmed: 31996766
Clin Nutr. 2020 Feb;39(2):501-509
pubmed: 30846324
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32747470
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Cancer Med. 2020 Nov;9(21):7964-7978
pubmed: 32924316
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
J Clin Oncol. 2015 Jan 1;33(1):90-9
pubmed: 25422490
Oral Oncol. 2011 Sep;47(9):910-4
pubmed: 21802345
Aging (Albany NY). 2012 Aug;4(8):535-46
pubmed: 22935594
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Autoimmun Rev. 2018 May;17(5):518-529
pubmed: 29526638
Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24
pubmed: 16149284
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
BMC Med. 2020 Apr 20;18(1):87
pubmed: 32306958
J Clin Med. 2019 Apr 03;8(4):
pubmed: 30987236
Oral Oncol. 2017 Aug;71:67-74
pubmed: 28688694
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
Support Care Cancer. 2020 Oct;28(10):4613-4625
pubmed: 32533436
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Maturitas. 2017 Feb;96:10-15
pubmed: 28041587
Int Immunopharmacol. 2020 Nov;88:106907
pubmed: 33182031
Medicine (Baltimore). 2020 Feb;99(7):e19059
pubmed: 32049805
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1159-1165
pubmed: 28448668